Replies to post #964 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

MRK's C-EDGE SVR4 data are ok but nothing special: #msg-112517399.

[semi_infinite]

From Barron's writeup with regard to Citigroup analyst -

"Werber also doesn’t see the results as a true challenge to Harvoni, as this regimen too takes 12 weeks—an extra month than Gilead’s drug—but it could be competitive with Merck’s."

I am interested in your take.